-
Apr 19, 2013 07:25AM
Vertex (VRTX) PT Goes to $95 at Needham & Company after Strong Data
-
Oct 12, 2012 08:29AM
Analyst Says Vertex (VRTX) Drug Data Shows "At Least Moderate Impact"
-
Jul 31, 2012 08:31AM
Needham & Company Reiterates a 'Buy' on Vertex (VRTX); Incivek Sales Continue to Fall, But Initial ALS-2200 Data Are Encouraging
-
Jul 18, 2012 01:10PM
Needham & Company Maintains a 'Buy' on Vertex (VRTX); Adjusting Q2 Lower, But Positive on Cash Flow
-
Jun 29, 2012 08:16AM
Needham & Company Reiterates a 'Buy' on Vertex (VRTX); Combination Trial in CF Encouraging
-
May 29, 2012 10:35AM
Needham & Company Maintains Bullish Stance on Vertex (VRTX) Despite Weaker Data
-
May 8, 2012 11:02AM
Notable Analyst Rating Changes 05/08: (VRTX) (XCO) (EA) Upgraded; (EP) (BP) (AMX) Downgraded
-
May 8, 2012 08:00AM
Needham & Company Upgrades Vertex (VRTX) to Buy; Positive Interim VX-809/Kalydeco Results; Large Market Opp
-
Apr 17, 2012 07:40AM
Needham & Company Maintains a 'Hold' on Vertex (VRTX); Q1 Preview
-
Jan 31, 2012 04:12PM
Needham & Company Maintains a 'Hold' on Vertex (VRTX); Surprisingly Early Approval of Kalydeco for G551D Cystic Fibrosis
-
Dec 23, 2011 07:35AM
Needham & Company 2012 Biotech Preview
-
Nov 8, 2011 09:15AM
Needham & Company Maintains a 'Hold' on Vertex (VRTX); AASLD Meeting Update
-
Oct 28, 2011 08:46AM
Needham & Company Maintains a 'Hold' on Vertex (VRTX); Incivek Sales Exceed Expectations Again, But Growth Appears to Be Slowing
-
Sep 22, 2011 04:40PM
Needham & Company Maintains a 'Hold' on Vertex (VRTX); Raising Incivek Sales Estimates, But Concerns Remain
-
May 26, 2011 11:15AM
Notable Analyst Rating Changes 05/26: (HST) (FITB) (CTSH) Upgraded; (RSH) (LULU) (CAVM) Downgraded
-
May 4, 2011 09:14AM
Needham & Company Maintains a 'Hold' on Vertex (VRTX); 1Q11 Review; Vertex Ready for Incivek Approval and Launch
-
Apr 29, 2011 10:25AM
Needham & Company Maintains a 'Hold' on Vertex (VRTX); Telaprevir Gets Enthusiastic Endorsement from FDA Advisory Committee, But Concerns Remain
-
Feb 23, 2011 12:33PM
Needham & Company Maintains a 'Hold' on Vertex (VRTX); Positive VX-770 Phase 3 Outcome in CF, But High Investor Expectations for HCV Program
-
Sep 8, 2010 02:52PM
Needham & Company Downgraded Vertex (VRTX) to Hold
-
May 26, 2010 07:39AM
Needham & Company Reiterates a 'Buy' on Vertex Pharmaceuticals (VRTX); Encouraging Top-Line Results from Phase 3 ADVANCE Trial
-
Apr 22, 2010 07:57AM
Needham & Company Reiterates a 'Buy' on Vertex Pharmaceuticals (VRTX); Room for Upside Around Phase 3 ADVANCE Results
-
Jan 12, 2010 08:42AM
Needham & Co Reiterates a 'Buy' on Vertex Pharmaceuticals (VRTX); Raises Price Target
-
Sep 26, 2008 08:52AM
Needham & Co Upgrades Vertex Pharmaceuticals (VRTX) to Buy